Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Otsuka, Ionis Extend HAE Licensing Pact into Asia
Otsuka Pharmaceutical said on June 18 that it has agreed with Ionis Pharmaceuticals to expand their licensing deal for the RNA therapy specialist’s investigational hereditary angioedema (HAE) treatment donidalorsen to now cover Asia-Pacific including Japan. An antisense oligonucleotide, donidalorsen is…
To read the full story
Related Article
- Otsuka/Ionis’ HAE Drug Dawnzera Approved in Europe
January 22, 2026
- Otsuka/Ionis’ HAE Prevention Drug Wins CHMP Backing
November 18, 2025
- Otsuka/Ionis’ HAE Drug Now under European Review
January 7, 2025
- Otsuka Bags European Commercial Rights to Ionis’ HAE Drug
December 20, 2023
BUSINESS
- Chugai Forms Strategic Investment Unit to Deepen Innovation Push; Record Japan Filings Eyed
July 27, 2026
- Chugai Notches Strong H1 Growth on Key Products, Roche Exports
July 27, 2026
- Meiji’s Hiyasta Hits PIII Goal in Advanced Melanoma
July 27, 2026
- China First to Approve Takeda’s Oveporexton for Narcolepsy
July 24, 2026
- FRONTEO Expects First US User of KIBIT AI Engine This Year: CEO
July 24, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…